nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.08.2009 | Original Article

Factors associated with bone density in young women with karyotypically normal spontaneous premature ovarian failure

verfasst von: Paula Leite-Silva, Aloísio Bedone, Aarão Mendes Pinto-Neto, José Vilton Costa, Lúcia Costa-Paiva

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate bone density and associated factors in women with premature ovarian failure (POF) compared to age-matched women with normal ovarian function.

Methods

A cross-sectional study of 50 patients with POF undergoing bone mineral densitometry was conducted, compared to 50 women paired by age who menstruated regularly.

Results

In women with POF, the mean bone mineral density measured was 1.22 g/cm² at the spine and 0.92 g/cm² at the femur, values which were significantly lower than in the control group (P < 0.0001). Factors directly associated with bone density of the lumbar spine were age and with bone density of the femur were BMI and reproductive age.

Conclusion

Young women with POF have a decrease in lumbar spine and femoral bone density. Age, reproductive age and BMI were the factors associated with BMD. These women need early investigation and treatment to prevent bone loss and minimize fracture risk in the future.

Matkovic V, Jelic T, Wardlaw GM, Ilich JZ, Goel PK, Wright JK et al (1994) Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. J Clin Invest 93:799–808. doi:10.1172/JCI117034 PubMedCrossRef

Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V et al (2000) Peak bone mass. Osteoporos Int 11:985–1009. doi:10.1007/s001980070020 PubMedCrossRef

McGuigan FE, Murray L, Gallagher A, Davey-Smith G, Neville CE, Van’t Hof R, Boreham C, Ralston SH (2002) Genetic and environmental determinants of peak bone mass in young men and women. J Bone Miner Res 17(7):1273–1279. doi:10.1359/jbmr.2002.17.7.1273 PubMedCrossRef

Abrams SA (2003) Normal acquisition and loss of bone mass. Horm Res 60(Suppl 3):71–76. doi:10.1159/000074505 PubMedCrossRef

Bachrach LK (2001) Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol Metab 12(1):22–28. doi:10.1016/S1043-2760(00)00336-2 PubMedCrossRef

Lazcano-Ponce E, Tamayo J, Cruz-Valdez A, Diaz R, Hernandez B, Del Cueto R et al (2003) Peak bone mineral area density and determinants among females aged 9 to 24 years in Mexico. Osteoporos Int 14:539–547. doi:10.1007/s00198-002-1363-2 PubMedCrossRef

Vartej P, Poiana C, Vartej I (2001) Effects of hyperprolactinemia on osteoporotic fracture risk in premenopausal women. Gynecol Endocrinol 15(1):43–47. doi:10.1080/713602650 PubMedCrossRef

Benetti-Pinto CL, Bedone A, Magna LA, Marques-Neto JF (2002) Factors associated with the reduction of bone density in patients with gonadal dysgenesis. Fertil Steril 77(3):571–575. doi:10.1016/S0015-0282(01)03215-0 PubMedCrossRef

Devleta B, Adem B, Senada S (2004) Hypergonadotropic amenorrhea and bone density: new approach to an old problem. J Bone Miner Metab 22(4):360–364. doi:10.1007/s00774-004-0495-1 PubMedCrossRef

10.

Riggs BL (2002) Endocrine causes of age-related bone loss and osteoporosis. Novartis Found Symp 242:247–259. doi:10.1002/0470846542.ch15 PubMedCrossRef

11.

Recker R, Lappe J, Davies K, Heaney R (2000) Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 15:1965–1973. doi:10.1359/jbmr.2000.15.10.1965 PubMedCrossRef

12.

Sagsveen M, Farmer JE, Prentice A, Breeze A (2003) Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density (review). Cochrane Database Syst Rev 4:CD001297

13.

North American Menopause Society (2006) Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause 13(3):340–367. doi:10.1097/01.gme.0000222475.93345.b3 CrossRef

14.

Gallagher JC (2007) Effect of early menopause on bone mineral density and fractures. Menopause 14(3):567–571. doi:10.1097/gme.0b013e31804c793d PubMedCrossRef

15.

Conway GS, Kaltsas G, Patel A, Davies MC, Jacobs HS (1996) Characterization of idiopathic premature ovarian failure. Fertil Steril 65(2):337–341PubMed

16.

Coulam CB, Adamson SC, Annagers JF (1986) Incidence of premature ovarian failure. Obstet Gynecol 67:604–606PubMed

17.

Goswami D, Conway GS (2005) Premature ovarian failure. Hum Reprod Update 11(4):391–410. doi:10.1093/humupd/dmi012 PubMedCrossRef

18.

Beck-Peccoz P, Persani L (2006) Premature ovarian failure. Orphanet J Rare Dis 6:1–9

19.

Van der Voort DJ, nan der Weijer PH (2003) Early menopause: increased fracture risk at older age. Osteoporos Int 14:525–530. doi:10.1007/s00198-003-1408-1 CrossRef

20.

Anasti J, Kalantaridou SN, Kimzey LM, Defensor RA, Nelson LM (1998) Bone loss in young women with kariotipically normal spontaneous premature ovarian failure. Obstet Gynecol 91:12–15. doi:10.1016/S0029-7844(97)00583-8 PubMedCrossRef

21.

Sugimoto AK, Hodsman AB, Nisker JA (1993) Long-term gonadotropin-releasing hormone agonist with standard postmenopausal estrogen replacement failed to prevent vertebral bone loss in premenopausal women. Fertil Steril 60(4):672–674PubMed

22.

World Health Organization (1994) Assesment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO, Geneva, 130p (report series, 843)

23.

Richelson LS, Wahner HW, Melton LJIII, Riggs BL (1984) Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 311:1273–1275PubMed

24.

Ohta H, Sugimoto I, Masuda A, Komukai S, Suda Y, Makita K, Takamatsu K, Horiguchi F, Nozawa S (1996) Decreased bone mineral density associated with early menopause progresses for at least ten years: cross-sectional comparisons between early and normal menopausal women. Bone 18(3):227–231. doi:10.1016/8756-3282(95)00480-7 PubMedCrossRef

25.

Hadjidakis D, Kokkinakis E, Sfakianakis M, Raptis SA (2003) Bone density patterns after normal and premature menopause. Maturitas 44(4):279–286. doi:10.1016/S0378-5122(03)00040-9 PubMedCrossRef

26.

Kritz-Silverstein D, Barrett-Connor E (1993) Early menopause, number of reproductive years and bone mineral density in postmenopausal women. Am J Public Health 83:983–988PubMedCrossRef

27.

Jayasinghe Y, Grover SR, Zacharin M (2008) Current concepts in bone and reproductive health in adolescents with anorexia nervosa. BJOG 115(3):304–315. doi:10.1111/j.1471-0528.2007.01601.x PubMedCrossRef

28.

Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH (2002) Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 287(20):2668–2676. doi:10.1001/jama.287.20.2668 PubMedCrossRef

29.

Miller KK, Klibanski A (1999) Amenorrheic bone loss. J Clin Endocrinol Metab 84(6):1775–1783. doi:10.1210/jc.84.6.1775 PubMedCrossRef

30.

Csermely T, Halvax L, Schmidt E, Zámbó K, Vadon G, Szabó I, Szilágyi A (2002) Occurrence of osteopenia among adolescent girls with oligo/amenorrhea. Gynecol Endocrinol 16(2):99–105. doi:10.1080/713603028 PubMedCrossRef

31.

Emans SJ, Grace E, Hoffer FA, Gundberg C, Ravnikar V, Woods ER (1990) Estrogen deficiency in adolescents and young adults: impact on bone mineral content and effects of estrogen replacement therapy. Obstet Gynecol 76(4):585–592PubMed

32.

Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312(7041):1254–1259PubMed

33.

Pouilles JM, Tremollieres F, Ribot C (1993) Spine and femur densitometry at the menopause: are both sites necessary in the assessment of the risk of osteoporosis? Calcif Tissue Int 52(5):344–347. doi:10.1007/BF00310196 PubMedCrossRef

34.

Myerson M, Gutin B, Warren MP, Wang J, Lichtman S, Pierson RN Jr (1992) Total body bone density in amenorrheic runners. Obstet Gynecol 79(6):973–978PubMed

35.

Morin S, Tsang JF, Leslie WD (2008) Weight and body mass index predict bone mineral density and fractures in women aged 40 to 59 years. Osteoporos Int (Jul 17)

36.

De Laet C, Kanis JA, Odén A et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16(11):1330–1338. doi:10.1007/s00198-005-1863-y PubMedCrossRef

37.

Cauley JA, Robbins J, Chen Z, et al., Women’s Health Initiative Investigators (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290(13):1729–1738. doi:10.1001/jama.290.13.1729

38.

Jackson RD, Wactawski-Wende J, LaCroix AZ, et al., Women’s Health Initiative Investigators (2006) Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women’s health initiative randomized trial. J Bone Miner Res 21(6):817–828. doi:10.1359/jbmr.060312

Titel: Factors associated with bone density in young women with karyotypically normal spontaneous premature ovarian failure
verfasst von: Paula Leite-Silva
Aloísio Bedone
Aarão Mendes Pinto-Neto
José Vilton Costa
Lúcia Costa-Paiva
Publikationsdatum: 01.08.2009
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 2/2009
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-008-0881-3

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Factors associated with bone density in young women with karyotypically normal spontaneous premature ovarian failure

Abstract

Objective

Methods

Results

Conclusion

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

Update Gynäkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

An extraordinary cause of vertebral fracture in pregnant woman: brucellosis

Accessory breast tissue presenting as a vulvar mass in an adolescent girl

What happens when vacuum extraction fails?

Peritoneal tuberculosis with elevated serum Ca-125 level mimicking advanced stage ovarian cancer: a case report

Inhibin A levels and severity of preeclampsia

Cystic adenomatoid malformation of the lung causing hydrops fetalis: case report and review of the literature

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

Update Gynäkologie